Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Shah, M.H., Lorigan, P., O'Brien, M.E. et al. (5 more authors) (2016) Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Investigational New Drugs, 34 (3). pp. 290-299. ISSN 0167-6997

Abstract

Metadata

Authors/Creators:
  • Shah, M.H.
  • Lorigan, P.
  • O'Brien, M.E.
  • Fossella, F.V.
  • Moore, K.N.
  • Bhatia, S.
  • Kirby, M.
  • Woll, P.J.
Copyright, Publisher and Additional Information: © The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Antibody-drug conjugate; CD56; DM1; IMGN901; Lorvotuzumab mertansine
Dates:
  • Published: June 2016
  • Published (online): 9 March 2016
  • Accepted: 26 February 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 24 May 2016 11:25
Last Modified: 24 May 2016 11:25
Published Version: http://dx.doi.org/10.1007/s10637-016-0336-9
Status: Published
Publisher: Springer Verlag (Germany)
Refereed: Yes
Identification Number: https://doi.org/10.1007/s10637-016-0336-9
Related URLs:

Share / Export

Statistics